09:52 AM EST - Acerus Pharmaceuticals Corporation : Will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc., which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.14.
